Phase III randomized trial of interleukin-2 with or without lymphokine- activated killer cells in the treatment of patients with advanced renal cell carcinoma Academic Article Article uri icon


MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Urinary Bladder Neoplasms


  • The dose and schedule of IL-2 used in this study resulted in a low level of antitumor activity and the addition of LAK did not improve the response rate against RCC. Given the infrequent, but reproducible, responses with IL-2 and interferon-based regimens, continued investigation of these agents is warranted as is the study of new cytokines. Alternative treatment strategies should be studied in RCC and new agents and treatment regimens that appear promising in Phase II studies must be studied in randomized trials.

publication date

  • September 6, 1995



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N

PubMed ID

  • 8625186

Additional Document Info

start page

  • 824

end page

  • 32


  • 76


  • 5